Nasdaq: YD Bio Completes Merger With Breeze

YD Bio shares will begin trading on the Nasdaq after completing a merger with Breeze. The merger was announced earlier this year and is expected to provide YD Bio with increased access to capital and resources. The company's shares will begin trading under the ticker symbol "YD" on the Nasdaq stock exchange.

YD Bio Limited (NASDAQ: YDES), a biotechnology company specializing in DNA methylation-based cancer detection technology and ophthalmologic innovations, has successfully completed its business combination with Breeze Holdings Acquisition Corp. The company will begin trading on the Nasdaq Global Market on August 29, 2025, under the ticker symbols "YDES" and "YDESW" for common stock and warrants, respectively.

The merger, announced earlier this year, marks a significant milestone for YD Bio. The company secured over $11.5 million in funding through a PIPE offering and trust proceeds, which will be used to advance its pipeline of innovative healthcare solutions. The funding will support YD Bio's core programs, including a blood-based cancer detection technology for early detection of pancreatic cancer and a monitoring test for recurrent breast cancer, which is expected to launch later this year.

In addition to cancer diagnostics, YD Bio is developing stem cell- and exosome-based therapies for ocular diseases such as dry eye syndrome, glaucoma, and corneal injury. Clinical development efforts are underway, with plans to initiate trials evaluating exosome-based contact lenses and artificial tears in 2027.

The company's business model focuses on partnerships with biopharmaceutical companies to transform innovative technologies into commercially viable drugs and diagnostics. YD Bio's multi-decade exclusive licensing agreements and proprietary patented technologies provide a significant first-mover advantage across its clinical markets.

The merger with Breeze Holdings Acquisition Corp. positions YD Bio as an emerging leader in the biotech industry with strong growth potential across multiple fast-growing healthcare markets. By entering the public markets, YD Bio is poised to accelerate innovation, scale production, and drive the development and commercialization of groundbreaking technologies.

[1] https://www.biospace.com/press-releases/yd-bio-limited-announces-closing-of-business-combination-and-listing-on-the-nasdaq-global-market
[2] https://www.stocktitan.net/news/YDES/yd-bio-limited-announces-closing-of-business-combination-and-listing-8ljcqne4wcp2.html